文献速递生殖医学

ω-3脂肪酸补充与自然受孕概率的关联研究

Omega-3 fatty acid supplementation and fecundability.
PubMed 文献 · Hum Reprod · 2022-01-01

本研究为「受孕时间(TTC)」前瞻性队列研究的二次分析,纳入900名无不孕史、尝试受孕不足3个月的30-44岁女性共2510个月经周期。校正年龄、肥胖、种族、既往妊娠及维生素使用后,自报使用ω-3脂肪酸补充剂者自然受孕概率为未使用者的1.51倍(95%CI 1.12-2.04)。

要点

  • 前瞻性记录示ω-3补充与自然受孕概率升高相关(受孕概率比1.51,95%CI 1.12-2.04)。
  • 使用ω-3者多较年轻、偏瘦、无妊娠史、白人,且更常服维生素D及复合维生素。
  • 研究非随机对照试验,补充剂种类品牌及剂量不一,无法比较剂量效应关系。

核心结论

  • 前瞻性记录的ω-3补充剂使用与自然受孕概率升高相关,校正年龄、肥胖、种族、既往妊娠及维生素D、复合维生素使用后受孕概率比为1.51(95%CI 1.12-2.04)。
  • 作者认为ω-3补充可能是改善生育力的可行且廉价的的可调节因素,但需随机对照试验进一步研究其对自然受孕女性的益处。

研究设计与样本

  • 研究为「受孕时间(TTC)」前瞻性时间-妊娠队列研究的二次数据分析,纳入900名女性共2510个月经周期。
  • 研究时间为2008年至2015年12月,研究对象为30-44岁、尝试受孕不足3个月、无不孕史的女性。
  • 采用标准化妊娠检测随访,女性每日记录月经周期事件及补充剂和药物摄入,ω-3使用定义为某月经周期中至少20%天数使用。
  • 采用离散时间Cox比例风险模型计算受孕概率比。

主要发现

  • 使用ω-3补充剂的女性相比未使用者更年轻、更瘦、无妊娠史、白人比例更高,且更常服用维生素D、产前及复合维生素。
  • 校正年龄、肥胖、种族、既往妊娠、维生素D及产前和复合维生素使用后,使用ω-3补充剂者受孕概率为未使用者的1.51倍(95%CI 1.12, 2.04)。

关键数值与推荐

  • ω-3使用定义为某月经周期中至少20%天数使用补充剂。
  • 受孕概率比1.51(95%CI 1.12, 2.04),使用ω-3补充剂者 vs 未使用者。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为ω-3补充可能是改善生育力的可行且廉价的的可调节因素,需随机对照试验进一步研究。

局限性

  • 研究不是随机对照试验。
  • 使用ω-3补充剂的女性可能代表更注重健康的人群,研究通过在模型中校正多个因素来试图处理这一问题。
  • TTC参与者使用的ω-3脂肪酸补充剂包括多种类型和品牌,ω-3脂肪酸剂量不一。
  • 女性报告了所服补充剂类型但未报告其中ω-3浓度,因此无法比较剂量或剂量-反应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is self-reported use of omega-3 fatty acid supplements associated with fecundability, the probability of natural conception, in a given menstrual cycle? SUMMARY ANSWER: Prospectively recorded omega-3 supplement use was associated with an increased probability of conceiving. WHAT IS KNOWN ALREADY: In infertile women, omega-3 fatty acid intake has been associated with increased probability of pregnancy following IVF. In natural fertility, studies are conflicting, and no study of natural fertility has evaluated omega-3 fatty acid supplementation and fecundity. STUDY DESIGN, SIZE, DURATION: Secondary data analysis of 900 women contributing 2510 cycles in Time to Conceive (TTC), a prospective, time to pregnancy cohort study from 2008 to December 2015. PARTICIPANTS/MATERIALS, SETTING, METHODS: Women aged 30-44 years, trying to conceive <3 months, without history of infertility were followed using standardized pregnancy testing. While attempting to conceive, women daily recorded menstrual cycle events and supplement and medication intake using the Cerner Multum Drug Database. Supplements and vitamins containing omega-3 were identified. Omega-3 use, defined as use in at least 20% of days in a given menstrual cycle, in each pregnancy attempt cycle was determined. A discrete-time Cox proportional hazards model was used to calculate the fecundability ratio. MAIN RESULTS AND THE ROLE OF CHANCE: Women taking omega-3 supplementation were more likely to be younger, thinner, nulligravid, white and to take vitamin D, prenatal and multivitamins compared to women not taking omega-3s. After adjusting for age, obesity, race, previous pregnancy, vitamin D and prenatal and multivitamin use, women taking omega-3 supplements had 1.51 (95% CI 1.12, 2.04) times the probability of conceiving compared to women not taking omega-3s. LIMITATIONS, REASONS FOR CAUTION: Our study was not a randomized controlled trial. The women who used omega-3 supplements may represent a more health-conscious population. We sought to address this by adjusting for multiple factors in our model. Additionally, the omega-3 fatty acid supplements that TTC participants used included multiple types and brands with varying dosages of omega-3 fatty acids. Women reported the type of supplement they were taking but not the concentration of omega-3s in that supplement. It is therefore not possible to compare dosing or a dose-response relationship in our study. WIDER IMPLICATIONS OF THE FINDINGS: Omega-3 supplementation may present a feasible and inexpensive modifiable factor to improve fertility. Randomized controlled trials are needed to further investigate the benefits of omega-3 supplementation for women trying to conceive naturally. STUDY FUNDING/COMPETING INTERESTS: This study was supported by the Division of Reproductive Endocrinology and Infertility at the University of North Carolina at Chapel Hill, the NIH/NICHD (R21 HD060229-01 and R01 HD067683-01), and in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (Z01ES103333). The authors declare that there is no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Stanhiser J, Jukic AMZ, McConnaughey DR, et al. Omega-3 fatty acid supplementation and fecundability. Hum Reprod. 2022. PMID: 35147198. doi:10.1093/humrep/deac027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。